PharmaJet

PharmaJet develops needle-free injection systems intended to replace conventional needle-and-syringe administration of injectable vaccines and therapeutics. The company positions its devices for use across a range of therapeutic areas, including prophylactic and therapeutic vaccines for infectious disease prevention and cancer treatments. Its product line includes the Tropis intradermal needle-free injection system, which is used in vaccination programs such as polio immunization and is also being evaluated as a delivery system for the tuberculin skin test.

The company markets the systems on the basis that they require no reformulation of the drug product and use the same fill/finish manufacturing process as existing injectables, with what it describes as an established regulatory pathway and commercially scaled, reusable devices. For healthcare providers, PharmaJet cites cited third-party study results on vaccinator preference, immunization coverage, workflow speed, and the elimination of sharps, needlestick injuries and needle reuse; for patients, it cites reported reductions in pain and soreness, high caregiver preference, reduced adverse events, and potential for home or self-administration.

Business model

PharmaJet partners with pharmaceutical companies to pair its needle-free injection systems with their injectable products, and supplies reusable devices to healthcare providers and immunization programs.

Traction

The Tropis needle-free injection system was selected to deliver 1.4 million polio vaccine doses in Nigeria (announced May 2026), and a Brazilian tuberculosis research network is evaluating the Tropis intradermal device as a delivery system for the tuberculin skin test (announced March 2026). The company cites published study data including 97% vaccinator preference, 18.4% improved immunization coverage, 25% faster workflow, 87% of patients reporting no pain, and a 54% reduction in adverse events.